Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.40 +7.6%	$2.53	$1.78 ▼ $10.14	$50.14M	0.7	266,023 shs	161,373 shs
BDTX Black Diamond Therapeutics	$2.50	$2.18	$1.20 ▼ $6.75	$142.15M	2.71	1.55 million shs	592,130 shs
PASG Passage Bio	$0.41 -6.2%	$0.38	$0.26 ▼ $1.33	$25.23M	1.67	376,161 shs	428,850 shs
TCRR TCR2 Therapeutics	$1.48	$1.65	$0.82 ▼ $3.88	$58.11M	1.95	494,777 shs	N/A
TSHA Taysha Gene Therapies	$2.42 +3.4%	$2.51	$1.05 ▼ $3.31	$519.48M	0.97	2.92 million shs	2.31 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	-6.50%	+3.72%	-21.20%	-34.41%	-67.63%
BDTX Black Diamond Therapeutics	-3.10%	+0.81%	-3.10%	+100.00%	-44.07%
PASG Passage Bio	-6.07%	+8.17%	+2.41%	+32.82%	-52.73%
TCRR TCR2 Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TSHA Taysha Gene Therapies	-2.50%	+1.30%	-17.61%	+107.08%	+13.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.0469 of 5 stars	3.4	3.0	0.0	4.8	0.0	2.5	0.6
BDTX Black Diamond Therapeutics	3.0955 of 5 stars	3.5	3.0	0.0	0.0	3.6	1.7	0.6
PASG Passage Bio	2.4246 of 5 stars	3.5	3.0	0.0	0.0	0.0	1.7	1.3
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	3.1408 of 5 stars	4.5	1.0	0.0	0.0	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	891.67% Upside
BDTX Black Diamond Therapeutics	3.00	Buy	$12.80	412.00% Upside
PASG Passage Bio	3.00	Buy	$7.50	1,747.29% Upside
TCRR TCR2 Therapeutics	0.00	N/A	N/A	N/A
TSHA Taysha Gene Therapies	3.00	Buy	$8.20	238.84% Upside

Current Analyst Ratings Breakdown

Latest TSHA, TCRR, BDTX, PASG, and ADVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	50.14	N/A	N/A	$3.40 per share	0.71
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$1.47 per share	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	$0.99 per share	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	$2.58 per share	N/A
TSHA Taysha Gene Therapies	$8.33M	62.36	N/A	N/A	$0.35 per share	6.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
BDTX Black Diamond Therapeutics	-$69.68M	$0.06	41.67	N/A	N/A	N/A	4.70%	3.47%	8/5/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$1.02	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)
TCRR TCR2 Therapeutics	-$151.82M	-$4.20	N/A	N/A	N/A	N/A	-97.81%	-69.35%	N/A
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest TSHA, TCRR, BDTX, PASG, and ADVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
BDTX Black Diamond Therapeutics	N/A	9.24	9.24
PASG Passage Bio	N/A	3.74	3.74
TCRR TCR2 Therapeutics	N/A	2.96	2.96
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
BDTX Black Diamond Therapeutics	95.47%
PASG Passage Bio	53.48%
TCRR TCR2 Therapeutics	64.76%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
BDTX Black Diamond Therapeutics	5.97%
PASG Passage Bio	4.30%
TCRR TCR2 Therapeutics	25.01%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	53.47 million	Optionable
PASG Passage Bio	130	62.15 million	59.48 million	Optionable
TCRR TCR2 Therapeutics	137	39.26 million	29.44 million	Not Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

TSHA, TCRR, BDTX, PASG, and ADVM Headlines

Recent News About These Companies

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock

July 1, 2025 | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLC

July 1, 2025 | marketbeat.com

Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data

June 29, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What Happened

June 26, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.comQ

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

June 3, 2025 | globenewswire.com

6TSHA : Where Taysha Gene Therapies Stands With Analysts

June 2, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, TCRR, BDTX, PASG, and ADVM Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.40 +0.17 (+7.62%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+0.79%)

As of 05:24 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Black Diamond Therapeutics NASDAQ:BDTX

$2.50 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.00 (+0.20%)

As of 05:40 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Passage Bio NASDAQ:PASG

$0.41 -0.03 (-6.24%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 +0.01 (+3.20%)

As of 05:58 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Taysha Gene Therapies NASDAQ:TSHA

$2.42 +0.08 (+3.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 -0.02 (-1.03%)

As of 04:40 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time